SOURCE: Mazal Plant Pharmaceuticals Inc.

January 22, 2007 09:45 ET

Mazal Plant Pharmaceuticals, Inc. Announced Today the Appointment of Mr. Stanley Fass as Interim President and Director

NEW YORK, NY -- (MARKET WIRE) -- January 22, 2007 -- Mazal Plant Pharmaceuticals, Inc. (PINKSHEETS: MZPP) (FRANKFURT: M9J) announced today the appointment of Mr. Stanley Fass as interim president and director. Mazal Plant Pharmaceuticals is actively seeking a joint venture with a major pharmaceutical company and believes that the previous experience of Mr. Fass will contribute significantly to this undertaking.

Mr. Fass previously served with Intec Pharma Ltd. where as Vice President, Business Development he successfully negotiated a joint venture with GSK. He also served for twelve years as President of Perio Products Ltd., where he successfully negotiated joint venture deals with Astra Pharmaceuticals, Procter & Gamble, Carter-Wallace, Colgate, Novartis, and AL Pharma, among others. Mr. Fass also has filed several Investigatory New Drug Applications (INDs) and a successful NDA approval with the FDA.

Dr. Mechael Kanovsky, CEO of Mazal Plant Pharmaceuticals, commented: "We are truly fortunate to benefit from the talents of Mr. Fass. Mr. Fass not only has a successful track record in identifying and negotiating joint ventures, but is also a highly regarded professional in the pharmaceutical world. We plan to utilize his talents and many years of experience to help our company meet its goals.

"Mazal Plant Pharmaceuticals is focusing its efforts this year to go about raising funds for its critical MAHDL phase I/II clinical trial. We have a number of different options and we are carefully weighing each option in order to achieve the maximum benefit to the company and to start the trial at the earliest possible convenience."

About Mazal Plant Pharmaceuticals, Inc.

Mazal Plant Pharmaceuticals, Inc. is an early-stage whole plant pharmaceutical development company whose mission is to develop treatments for chronic diseases from combinations of whole plants and to build shareholder value through negotiated relationships with strategic partners to fund commercialization and marketing of these treatments on a stand-alone or combination basis.

Additional information on Mazal Plant Pharmaceuticals, Inc. may be found at: http://www.mazal.cc/index.html.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, including statements regarding any potential sales of products as well as statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Mazal Plant Pharmaceuticals, Inc. to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Mazal Plant Pharmaceuticals, Inc.'s subsequent reports filed with the Securities and Exchange Commission under the Exchange Act. This press release speaks as of the date first set forth above and Mazal Plant Pharmaceuticals assumes no responsibility to update the information included herein for events occurring after the date hereof.

Contact Information

  • Contact:
    LC group
    Rick Lutz
    (404) 261-1196